AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34495340
Drug: Daily Sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Sublingual Buprenorphine-Naloxone (SLB)
Trial: 33283485
Drug: AKCEA‐TTR‐LRx 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKCEA‐TTR‐LRx 45 mg
Trial: 33283485
Drug: AKCEA‐TTR‐LRx 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKCEA‐TTR‐LRx 60 mg
Trial: 33283485
Drug: AKCEA‐TTR‐LRx 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKCEA‐TTR‐LRx 90 mg
Trial: 33283485
Drug: AKCEA‐TTR‐LRx 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AKCEA‐TTR‐LRx 120 mg (single dose)
Trial: 35123014
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with different illumination times
Trial: 35426781
Drug: i-gel® (supraglottic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel® (supraglottic airway)
Trial: 39222649
Drug: Gefapixant 45
RxNorm normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Gefapixant 45 mg twice daily
Trial: 33301646
Drug: POLST DNR/Limited
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POLST DNR/Limited Treatment
Trial: 33775313
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of BEV and Stupp protocol
Trial: 33798499
Drug: Meningococcal conjugate
RxNorm normalized name: meningococcal conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal conjugate control (MenACWY) vaccine
Trial: 32869124
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g TXA
Trial: 32869124
Drug: 2.0 g
RxNorm normalized name: Fifty50 2.0 Glucose Meter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 g TXA
Trial: 32869124
Drug: 3.0 g
RxNorm normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 g TXA
Trial: 32869124
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g TXA
Trial: 34599466
Drug: Bacillus coagulans
RxNorm normalized name: Bacillus coagulans
DrugBank: Bacillus coagulans (DB19246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus coagulans Unique IS2 with lactulose (15 mL suspension of probiotic (B. coagulans Unique IS2, 2 × 10^9 spores) with lactulose (10 g))
Trial: 32452846
Drug: Intravenous P2Y12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous P2Y12 inhibitor cangrelor
Trial: 36239434
Drug: No-cost cryotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-cost cryotherapy treatment
Trial: 36239434
Drug: Work, household
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Work, household obligations, and fear of treatment
Trial: 35253581
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (SCI) - 1cc triamhexal (n=25)
Trial: 32667287
Drug: Argatroban treatment
RxNorm normalized name: Argatroban
DrugBank: Argatroban (DB00278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Argatroban treatment for 7 days
Trial: 36137674
Drug: Drug-coated balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coated balloon (DCB) treatment
Trial: 32989795
Drug: Doravirine 100
RxNorm normalized name: doravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg twice daily coadministered with rifabutin
Trial: 32989795
Drug: Doravirine 100
RxNorm normalized name: doravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg once daily
Trial: 32086985
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of an encecalin standardized extract of Ageratina pichinchensis for 6 months
Trial: 34456283
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of bisphosphonate gel
Trial: 34456283
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of recombinant human bone morphogenic protein 2 gel
Trial: 34456283
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of a mixed formula of both gels
Trial: 34456283
Drug: Implant insertion
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant insertion without application of any medication (Control)
Trial: 32057490
Drug: BPPV diagnosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPPV diagnosis and treatment system
Trial: 35512719
Drug: Chimeric haemagglutinin
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric haemagglutinin influenza split‐virion vaccines adjuvanted with AS01
Trial: 35512719
Drug: Chimeric haemagglutinin
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric haemagglutinin influenza split‐virion vaccines adjuvanted with AS03
Trial: 35512719
Drug: Chimeric haemagglutinin
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric haemagglutinin influenza split‐virion vaccines non‐adjuvanted
Trial: 35703882
Drug: β-blockers (bisoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-blockers (bisoprolol 10 mg or atenolol 100 mg)
Trial: 34180428
Drug: Sham Mirror
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sham Mirror Therapy (C)
Trial: 33040810
Drug: Floium ginkgo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floium ginkgo extract and tertram ethypyrazine sodium chloride injection
Trial: 33040810
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment measures
Trial: 32011301
Drug: Amiodarone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone at a maintenance dose for one year (n=60)
Trial: 32464043
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of surgical and systemic therapies
Trial: 35984496
Drug: Concurrent bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent bilateral anodal tDCS of primary motor cortex and cerebellum (2 mA, 20 min)
Trial: 33879680
Drug: Biqi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biqi capsule combined with diclofenac sodium sustained release tablets
Trial: 33879680
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium sustained-release tablets alone
Trial: 32012411
Drug: Pembrolizumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab monotherapy 200 mg every 3 weeks for 2 years or until progression, death, unacceptable toxicity or consent withdrawal
Trial: 34971040
Drug: Tablet-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based training
Trial: 32266572
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three techniques (NIR, blue dye, RC)
Trial: 34401422
Drug: PA-TXA (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PA-TXA (15 mg/kg)
Trial: 34401422
Drug: IA-TXA (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA-TXA (2 g)
Trial: 34401422
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no TXA injection)
Trial: 34332584
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg daily for 24 weeks
Trial: 35202432
Drug: Probiotics supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics supplements orally twice a day for 3 months
Trial: 35202432
Drug: Placebo supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplements orally twice a day for 3 months
Trial: 35644993
Drug: Exercise-based cardiovascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise-based cardiovascular rehabilitation program (CR) with 3 weekly exercise sessions for 6 months
Trial: 35895508
Drug: Casirivimab and
RxNorm normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Casirivimab and Imdevimab (CAS + IMD) 2.4 g
Trial: 35895508
Drug: Casirivimab and
RxNorm normalized name: Casirivimab and Imdevimab
DrugBank: Casirivimab (DB15941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Casirivimab and Imdevimab (CAS + IMD) 8.0 g
Trial: 616191718
Drug: Complex decongestive
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex decongestive therapy (CDT) for 2 weeks
Trial: 33306110
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplements
Trial: 35775723
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor blocker exendin[9-39] (Ex-9)
Trial: 35775723
Drug: DPP4 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP4 inhibitor (sitagliptin)
Trial: 34325975
Drug: Hydrocortisone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (200 mg continuous infusion for 7 days)
Trial: 33740568
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol 1000 mg
Trial: 32457366
Drug: Water spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water spray (WS) applied every 15 minutes during exercise
Trial: 33755168
Drug: High-dose amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amoxicillin (875 mg) plus clavulanate (125 mg) twice a day for 7 days
Trial: 33755168
Drug: Standard-dose amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose amoxicillin (875 mg) plus clavulanate (125 mg) plus placebo, twice a day for 7 days
Trial: 33755168
Drug: High-dose amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose amoxicillin (875 mg) plus clavulanate (125 mg)
Trial: 33755168
Drug: Standard-dose amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose amoxicillin (875 mg) plus clavulanate (125 mg) plus placebo
Trial: 34256031
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg administered subcutaneously every 4 weeks for 28 weeks (extended to 52 weeks if needed)
Trial: 32359153
Drug: USDA‐LB (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USDA‐LB (150 g/d lean beef as an isocaloric replacement for carbohydrate)
Trial: 35953719
Drug: Obicetrapib 5
RxNorm normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obicetrapib 5 mg
Trial: 38705341
Drug: Obicetrapib 10
RxNorm normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obicetrapib 10 mg
Trial: 32051386
Drug: Post-DOAC hsCRP
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-DOAC hsCRP >0.100 mg/dL
Trial: 34212138
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and topical Tranexamic Acid (TXA)
Trial: 33788216
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D status in winter (25(OH)D concentration 26.9 nmol/L)
Trial: 33788216
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D status in summer (25(OH)D concentration 43.4 nmol/L)
Trial: 34979503
Drug: Boron-based gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron-based gel containing 3% sodium pentaborate pentahydrate
Trial: 34979503
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel with no chemical substance
Trial: 33892722
Drug: Inofolic (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inofolic (4 g myo‐inositol + 400 μg folic acid)
Trial: 33892722
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (400 μg)
Trial: 35114340
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day for 90 days
Trial: 35818296
Drug: oVRcome app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oVRcome app (self-guided virtual reality exposure and cognitive behaviour therapy)
Trial: 34417781
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (n = 45)
Trial: 34417781
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional treatment (control group, n = 46)
Trial: 34632865
Drug: Virtual game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Virtual game training using the SeeMe virtual game system (12 sessions of 30 minutes bi-weekly)
Trial: 32844575
Drug: Intradialytic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradialytic group laughter therapy (30-minute session once weekly for 8 weeks)
Trial: 32189678
Drug: Cold chain
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold chain equipment (CCEs) assessment using WHO‐UNICEF Effective Vaccine Management (EVM) tool
Trial: 32189678
Drug: Electrical vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical vaccine storage equipment
Trial: 32189678
Drug: Ice packs
RxNorm normalized name: Camphor Ice Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice packs preparation and storage capacity
Trial: 35526121
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) risedronate taken fasted (group A)
Trial: 35526121
Drug: Gastro-resistant (GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant (GR) formulation 1 taken fasted (group B)
Trial: 35526121
Drug: Gastro-resistant (GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant (GR) formulation 2 taken fasted (group C)
Trial: 35526121
Drug: Gastro-resistant (GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant (GR) formulation 3 taken fasted (group D)
Trial: 35526121
Drug: Gastro-resistant (GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant (GR) formulation 4 taken fasted (group E)
Trial: 35526121
Drug: Gastro-resistant (GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant (GR) formulation 1 taken with food (group F)
Trial: 35526121
Drug: Gastro-resistant (GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant (GR) formulation 2 taken with food (group G)
Trial: 35526121
Drug: Gastro-resistant (GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant (GR) formulation 3 taken with food (group H)
Trial: 35526121
Drug: Gastro-resistant (GR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant (GR) formulation 4 taken with food (group I)
Trial: 35202553
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg STM
Trial: 35202553
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg STM
Trial: 33736601
Drug: Warm solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm solution containing 30 ml 5% sodium bicarbonate solution and 15 ml reformulated simethicone emulsion
Trial: 33736601
Drug: 45 ml
RxNorm normalized name: ethanol 0.645 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 ml 40 °C lukewarm water
Trial: 33592607
Drug: Topical glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticoids (TGC)
Trial: 36075079
Drug: Weight-based enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based enoxaparin dosing (0.5 mg/kg every 12 hours)
Trial: 36075079
Drug: Fixed-dose enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose enoxaparin (40 mg daily for BMI < 40; 40 mg every 12 hours for BMI ≥ 40)
Trial: 35490599
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg for 2 weeks
Trial: 33346091
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy to the prostate bed (51 Gy in 15 fractions, 3.4 Gy per fraction)
Trial: 34250911
Drug: Single Bond
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Bond Universal Agent (Group A)
Trial: 34250911
Drug: Seal &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seal & Protect Agent (Group B)
Trial: 33815533
Drug: α-viniferin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-viniferin administered three times a day for ten days using a sterile cotton swab stick.
Trial: 33622079
Drug: Chemical bleaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical bleaching with 40% hydrogen peroxide (H2O2) gel
Trial: 33622079
Drug: 40% H2O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% H2O2 gel activated with the diode laser
Trial: 33446440
Drug: Pompage therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pompage therapy (24 sessions over 8 weeks, 40 minutes each, three times a week)
Trial: 33514367
Drug: Kaloba® tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaloba® tablet
Trial: 32720353
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation therapy (OAT) continued
Trial: 32401715
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta‐1b on alternate days for 14 days)
Trial: 32401715
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lopinavir 400 mg and ritonavir 100 mg every 12 h for 14 days)
Trial: 34209647
Drug: Self-guided forest
RxNorm normalized name: Fortesta
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-guided forest therapy
Trial: 34209647
Drug: Guided forest
RxNorm normalized name: Fortesta
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided forest therapy program
Trial: 36253714
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg GTN administered in the catheter immediately after recanalization
Trial: 36253714
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline administered in the catheter immediately after recanalization
Trial: 35788622
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (20 mg/d on days 1-5, then 10 mg/d on days 6-10)
Trial: 35788622
Drug: Standard dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dexamethasone (6 mg/d for 10 days)
Trial: 32472620
Drug: Alcohol beverage
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol beverage sufficient to produce a breath alcohol concentration of 0.08 g/dl
Trial: 33256237
Drug: Cell-based therapy
RxNorm normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell-based therapy
Trial: 32311473
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg intravenous linezolid
Trial: 32311473
Drug: 900- and
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 900- and 1200-mg linezolid doses
Trial: 32311473
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the standard dose of linezolid
Trial: 35802209
Drug: Mindfulness intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindfulness intervention in conjunction with behavioral treatment (BT)